Pembrolizumab for the treatment of renal cell carcinoma

References

• “Kidney and renal pelvis cancer — cancer stat facts.” [Online]. Available: https://seer.cancer.gov/statfacts/html/kidrp.html. [ Accessed: 21-Nov-2020].
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008 Nov;8(11):865–873.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Santoni M, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7: 1–8.
   PubMedGoogle Scholar
• Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res. 2014 Dec 01;2(12):1132–1141.
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug;25(4):793–812.
   PubMed Web of Science ®Google Scholar
• Ciccarese C, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep 01;49:37–44.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• McDermott DF, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J Clin Oncol. 2018 May;36(15_suppl):4500.
   Web of Science ®Google Scholar
• Lee J-L, et al. First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B. J Clin Oncol. 2020 May;38(15_suppl):5034.
   Google Scholar
• Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010 May;7(5):277–285.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019 May 04;19(5):397–407.
   PubMed Web of Science ®Google Scholar
• Bianchi C, et al. The glucose and lipid metabolism reprogramming is grade dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–113515.
   PubMedGoogle Scholar
• Ragone R, et al. Renal cell carcinoma: a study through NMR-based metabolomics combined with transcriptomics. Diseases. 2016 Jan;4(1):7.
   Google Scholar
• Lucarelli G, et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371–13386.
   PubMedGoogle Scholar
• Lucarelli G, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging (Albany. NY). 2018 Dec;10(12):3957–3985.
   PubMedGoogle Scholar
• Bombelli S, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020 Nov;190(11):2317–2326.
   PubMed Web of Science ®Google Scholar
• Landberg A, Fält A, Montgomery S, et al. Overweight and obesity during adolescence increases the risk of renal cell carcinoma. Int J Cancer. 2019 Sep;145(5):1232–1237.
   PubMed Web of Science ®Google Scholar
• Vuong L, Kotecha RR, Voss MH, et al. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019 Oct 01;9(10):1349–1357.
   PubMed Web of Science ®Google Scholar
• Tamma R, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol Semin Orig Investig. 2019 Jun;37(6):355.e11–355.e19.
   PubMed Web of Science ®Google Scholar
• Ghini V, et al. Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer. Cancers (Basel). 2020 Dec;12(12):1–16.
   Web of Science ®Google Scholar
• Hirsch L, Flippot R, Escudier B, et al. Immunomodulatory roles of VEGF pathway inhibitors in Renal Cell Carcinoma. Drugs. 2020 Aug 01;80(12):1169–1181.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009 Mar;9(3):162–174.
   PubMed Web of Science ®Google Scholar
• Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the checkmate 016 study. J Immunother Cancer. 2018;6(1).
   Web of Science ®Google Scholar
• Atkins MB, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405–415.
   Web of Science ®Google Scholar
• Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Taylor MH, et al. Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–1163.
   PubMed Web of Science ®Google Scholar
• “Keytruda | European Medicines Agency.” [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda. [ Accessed: 28-Nov-2020].
   Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758.
   PubMed Web of Science ®Google Scholar
• Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1563–1573.
   PubMed Web of Science ®Google Scholar
• Fessas P, Lee H, Ikemizu S, et al. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017 Apr 01;44(2):136–140.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Stühler V, Maas JM, Walz S, et al. An evaluation of avelumab for the treatment of genitourinary tumors. Expert Opin Biol Ther. 2020 Sep;20(9):971–979.
   PubMed Web of Science ®Google Scholar
• Hamid O, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588.
   PubMed Web of Science ®Google Scholar
• Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247–1253.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med. 2013 Jul;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Atkins MB, et al. Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: long-term efficacy and safety from a phase Ib study. J Clin Oncol. 5080–5080 May;38(15_suppl):2020.
   Web of Science ®Google Scholar
• Motzer R, et al. Lenvatinib plus pembrolizumab or everolimus for advanced Renal Cell Carcinoma. N Engl J Med. 2021 Apr;384(14):1289–1300.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482.
   PubMed Web of Science ®Google Scholar
• Lee C-H, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 5008–5008 May;38(15_suppl):2020.
   Web of Science ®Google Scholar
• Sibaud V, et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res. 2015;25(6):555–558.
   PubMed Web of Science ®Google Scholar
• Gaudy C, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015 Nov 01;38(11):e182–e183.
   PubMed Web of Science ®Google Scholar
• Zimmer L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:210–225.
   PubMed Web of Science ®Google Scholar
• McDermott DF, et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): results from KEYNOTE-427 cohort B. J Clin Oncol. 2019 Mar;37(7_suppl):546.
   Web of Science ®Google Scholar
• Kwok G, Yau TCC, Chiu JW, et al. Pembrolizumab (Keytruda). Hum Vaccines Immunother. 2016 Nov 01;12(11):2777–2789.
   PubMed Web of Science ®Google Scholar
• “EAU 2020: health-Related Quality-of-Life Analysis From KEYNOTE-426: pembrolizumab Plus Axitinib vs Sunitinib for Advanced Renal Cell Carcinoma.” [Online]. Available: https://www.urotoday.com/conference-highlights/eau-2020/kidney-cancer/123218-eau-2020-health-related-quality-of-life-analysis-from-keynote-426-pembrolizumab-plus-axitinib-vs-sunitinib-for-advanced-renal-cell-carcinoma.html. [ Accessed: 19-Dec-2020].
   Google Scholar
• Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Kahlmeyer A, et al. Expression of PD-1 and CTLA-4 are negative prognostic markers in Renal Cell Carcinoma. J Clin Med. 2019 May;8(5):743.
   Web of Science ®Google Scholar
• Yarchoan M, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019 Mar;4(6).
   PubMed Web of Science ®Google Scholar
• Zhu J, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018 Jan 25;6(1).
   PubMed Web of Science ®Google Scholar
• Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun;393(10189):2404–2415.
   PubMed Web of Science ®Google Scholar
• Jilaveanu LB, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5(3):166–172.
   PubMed Web of Science ®Google Scholar
• McDermott DF, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749–757.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, et al. Biomarker analyses from JAVELIN renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol. 2019 May;37(15_suppl):101.
   Web of Science ®Google Scholar
• Escudier B, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–720.
   PubMed Web of Science ®Google Scholar
• Bedke J, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol. 2021 Mar;79(3):339–342.
   PubMed Web of Science ®Google Scholar
• Cao G, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020 Aug 27;10(8):e034626.
   Web of Science ®Google Scholar
• “Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckM … | oncologyPRO.” [Online]. Available: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-cabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-first-results-from-the-randomized-phase-iii-checkmate-9er-trial. [ Accessed: 20-Dec-2020].
   Google Scholar
• Raimondi A, et al. Predictive biomarkers of response to immunotherapy in Metastatic Renal Cell Cancer. Front Oncol. 2020 Aug 12;10:1644.
   PubMed Web of Science ®Google Scholar
• Wang X, Lopez R, Luchtel RA, et al. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int. 2021 Jan 01;99(1):75–85.
   PubMed Web of Science ®Google Scholar